Atara Biotherapeutics, Inc.
ATRA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ATRA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ATRA
Atara Biotherapeutics, Inc. is a biotechnology company focused on developing and commercializing therapies for patients with serious medical conditions, including its lead product candidate tabelecleucel (tab-cel) for post-transplant lymphoproliferative disease (PTLD).
Key risk: Cash runway insufficient
BioSniper Score
Based on 6 of 6 signals
Market Cap
$92.3M
Cash Runway
9.6 moLead Asset
ATA3219 (Phase 1)
Next Catalyst
Phase3_Topline · Aug 1, 2030Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials · 1 catalyst for Atara Biotherapeutics, Inc..
Atara Biotherapeutics, Inc. is a biotechnology company focused on developing and commercializing therapies for patients with serious medical conditions, including its lead product candidate tabelecleucel (tab-cel) for post-transplant lymphoproliferative disease (PTLD).
- Lead product candidate tabelecleucel (tab-cel) is being developed for solid organ or allogeneic hematopoietic transplant patients with PTLD, with a Phase 3 topline readout expected around 2030-08-01 [catalyst].
- As of 2026-06-30, the company reported cash & equivalents of $3.2M, total revenue of $0.6M, net income of -$4.8M, and shareholders' equity of -$38.5M [sec].
- The company has incurred significant operating losses in every annual reporting period since inception, except for the fiscal year ended December 31, 2025, when it reported net income of $32.7M due to commercialization revenue and reduced expenses [sec_mda · as of 2026-03-16].
- Atara's existing cash, cash equivalents, and short-term investments as of June 30, 2026 are not sufficient to fund planned operations, raising substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-08-12].
- The company has transitioned tab-cel clinical trials and manufacturing activities to partner Pierre Fabre in 2025, and its future funding depends on milestone and royalty payments under the A&R Commercialization Agreement [sec_mda · as of 2026-08-12].
What works
- Atara achieved a net income of $32.7M for the fiscal year ended December 31, 2025, driven by commercialization revenue and significant reductions in operating expenses [sec_mda · as of 2026-03-16].
- The company has a partnership with Pierre Fabre for tab-cel, which includes milestone and royalty payments under the A&R Commercialization Agreement [sec_mda · as of 2026-08-12].
- Tabelecleucel is approved in the EEA, the UK, and Switzerland under the name Ebvallo, indicating some commercial traction [sec_mda · as of 2026-03-16].
What to weigh
- Atara's cash position of $3.2M as of 2026-06-30 is insufficient to fund planned operations, and the company has substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-08-12].
- The company has incurred significant operating losses in every annual reporting period since inception, except for 2025, and expects to continue incurring losses for the foreseeable future [sec_mda · as of 2026-03-16].
- Atara does not have any committed external source of funds other than milestone and royalty payments from Pierre Fabre, and those payments are subject to the terms of the HCRx Agreement [sec_mda · as of 2026-08-12].
- The company's Phase 1 study of ATA3219, an allogeneic anti-CD19 CAR-T, was terminated, indicating a setback in its pipeline [catalyst].
From the filings
Quoted directly from source documents.
Cash position is insufficient to fund operations
“Our existing cash, cash equivalents and short-term investments as of June 30, 2026 will not be sufficient to fund our planned operations”
SEC MD&A · August 12, 2026
Net income in 2025 due to commercialization revenue
“For the fiscal year ended December 31, 2025, we reported a net income of $32.7 million due to commercialization revenue combined with significant reductions in operating expenses.”
SEC MD&A · March 16, 2026
Tab-cel BLA filing and regulatory progress
“•File BLA in Q2 2024•Receive FDA acceptance of BLA filing in Q3 2024•Successfully Complete RTQs and PAI to enable BLA approval in HCT and SOT in Q1 2025”
SEC filings · April 28, 2025
Substantial doubt about going concern
“These conditions raise substantial doubt about our ability to continue as a going concern for at least 12 months after the issuance of the accompanying condensed consolidated financial statements.”
SEC MD&A · May 12, 2026
Catalyst timeline
- 2030-08-01 · Phase3_Topline · tabelecleucel — Phase 3 Topline: Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic — Topline results from the Phase 3 study of tabelecleucel for post-transplant lymphoproliferative disease are expected, which will be a key value driver for the program.
Risks & what to watch (4)›
Key risks
- Cash runway insufficient — Cash of $3.2M as of 2026-06-30 is not enough to fund planned operations, with substantial doubt about going concern [sec_mda · as of 2026-08-12].
- Dependence on partner payments — No committed external funding beyond milestone/royalty payments from Pierre Fabre, which are subject to HCRx Agreement terms [sec_mda · as of 2026-08-12].
- Historical operating losses — Incurred losses every year since inception except 2025; expects continued losses for the foreseeable future [sec_mda · as of 2026-03-16].
- Pipeline setback — Phase 1 study of ATA3219 (allogeneic anti-CD19 CAR-T) was terminated [catalyst].
What to watch
- Phase 3 topline data for tabelecleucel in solid organ or allogeneic hematopoietic transplant patients, expected around 2030-08-01 [catalyst].
- Ability to secure additional funding through equity offerings, debt financings, or strategic partnerships to address cash runway concerns [sec_mda · as of 2026-08-12].
- Progress of regulatory approvals for tab-cel in the US, including BLA filing and potential approval [sec · filed 2025-04-28].
- Milestone and royalty payments from Pierre Fabre under the A&R Commercialization Agreement [sec_mda · as of 2026-08-12].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Atara Biotherapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Atara Biotherapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
9.6 months
OCF -$3M · Net income -$5M
Lead: Phase 3
2 candidates
1 upcoming, next in ~1432d
1 buy · 3 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
30
Total value held
$8.8M
| Holder | Shares | Value |
|---|---|---|
| adage capital partners gp, l.l.c. | 700,000 | $3.3M |
| vanguard capital management llc | 435,724 | $2.1M |
| mackenzie financial corp | 313,620 | $1.5M |
| blackrock, inc. | 79,022 | $374K |
| geode capital management, llc | 66,146 | $313K |
| staley capital advisers inc | 50,000 | $237K |
| millennium management llc | 47,689 | $226K |
| jane street group, llc | 33,870 | $160K |
| vanguard fiduciary trust co | 33,621 | $159K |
| bridgeway capital management, llc | 32,691 | $155K |
Showing top 10 of 30 institutional holders of Atara Biotherapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 5.3%
- Days to cover
- 4.7
- Shares short
- 306,093
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ATRA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Atara Biotherapeutics, Inc.?
Atara Biotherapeutics, Inc. is a biotechnology company focused on developing and commercializing therapies for patients with serious medical conditions, including its lead product candidate tabelecleucel (tab-cel) for post-transplant lymphoproliferative disease (PTLD).
What is Atara Biotherapeutics, Inc.'s lead drug candidate?
Atara Biotherapeutics, Inc.'s most advanced tracked candidate is ATA3219 (Phase 1) for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
What is Atara Biotherapeutics, Inc.'s next catalyst?
Atara Biotherapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic " — expected August 1, 2030.
Who is the CEO of Atara Biotherapeutics, Inc.?
Dr. Anhco Nguyen Ph.D. is the chief executive officer of Atara Biotherapeutics, Inc. (ATRA).
Where is Atara Biotherapeutics, Inc. headquartered?
Atara Biotherapeutics, Inc. (ATRA) is headquartered in Thousand Oaks, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.